Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. News
  7. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
Real-time Quote. Real-time Euronext Paris - 06/15 07:58:09 am
3.994 EUR   +0.43%
06/03NOVACYT  : Launches Two New COVID-19 Tests
MT
06/03NOVACYT  : Launch of two new PCR COVID-19 assays
PU
05/31NOVACYT  : Monthly statement on outstanding equity shares and voting rights
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Novacyt S.A.: New Contract With UK DHSC for Instrument Platforms and COVID-19 Testing Kits

09/29/2020 | 02:01am EDT

Regulatory News:

Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) ("Novacyt" or the "Company"), an international specialist in clinical diagnostics, announces it has signed a new supply contract with the UK Department of Health and Social Care (DHSC) for its q16 and q32 Rapid-PCR instrument platforms, exsig® COVID-19 Direct kits and genesig® SARS-CoV-2 Winterplex kits.

This is the second major contract awarded by the DHSC to Primerdesign, the Company’s wholly owned molecular diagnostics division, during the COVID-19 pandemic and follows the ongoing contract announced on 27 April 2020 for the supply of its PCR COVID-19 test.

Under the terms of the contract, which is in two phases, Primerdesign will supply its products to the DHSC for up to six months. Phase one has an initial fixed term of 14 weeks with the potential to extend supply by a further 10 weeks. This first phase of the contract will involve the immediate deployment of 300 PCR instruments, related kits and support services with a minimum value of £150 million for the first 14 weeks. Based on this initial period, a further £100 million of revenue could be expected for the subsequent 10 weeks, however volumes can be varied up or down subject to certain notice criteria given by the DHSC.

The second phase of the contract, which is optional by the DHSC, allows for the provision of up to 700 additional PCR instruments, related kits and support services, as well as additional COVID-19 products from the Company’s portfolio where required. Depending upon the uptake, phase two of the contract could generate considerably more sales than the first phase.

The intended use of the contract is for Novacyt to support the urgent requirement for COVID-19 testing of patients in the NHS. In addition to the provision of products, the Company will also provide training and maintenance services for the q16 and q32 instrument platforms.

Novacyt has the capacity to meet the demand of both phases of this new contract, as well as to continue to build its sales across international markets.

Graham Mullis, Chief Executive Officer of Novacyt, added:
“I am delighted that Novacyt continues to play a key role in helping the UK fight the COVID-19 pandemic and this second DHSC contract reinforces the Company’s important position within UK diagnostics today. Through this contract, we will be working to support the NHS as we approach an expected challenging winter period. The ability to test multiple patients with our market leading COVID-19 kits and instruments designed to provide results in under 60 minutes will help to ensure vital NHS services can continue to function during these difficult times. I am immensely proud of what the Novacyt team continues to deliver and remain confident in the prospects of the business, not only for the short-term, but also for the longer-term.”

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com


© Business Wire 2020
All news about NOVACYT
06/03NOVACYT  : Launches Two New COVID-19 Tests
MT
06/03NOVACYT  : Launch of two new PCR COVID-19 assays
PU
05/31NOVACYT  : Monthly statement on outstanding equity shares and voting rights
CO
05/26GLOBAL MARKETS LIVE : Amazon, Volkswagen, AstraZeneca, Aston Martin, Sony...
05/26NOVACYT  : Launch of VersaLab™ Portable
PU
05/26NOVACYT S.A. ("NOVACYT", THE "COMPAN : Launch of VersaLab™ Portable
BU
05/21NOVACYT  : Government and Covid test supplier Novacyt row over £150m PCR contrac..
AQ
05/21NOVACYT  : DHSC Dispute Update
PU
05/21NOVACYT S.A. ("NOVACYT", THE "COMPAN : DHSC Dispute Update
BU
05/17LONDON STOCK EXCHANGE : Banks, industrial stocks drag FTSE 100 down; Diploma jum..
RE
More news
Financials
Sales 2020 312 M 378 M 378 M
Net income 2020 185 M 224 M 224 M
Net cash 2020 102 M 123 M 123 M
P/E ratio 2020 1,52x
Yield 2020 -
Capitalization 281 M 341 M 340 M
EV / Sales 2020 0,57x
EV / Sales 2021 0,37x
Nbr of Employees 110
Free-Float 99,2%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 4,90 €
Last Close Price 3,98 €
Spread / Highest target 43,3%
Spread / Average Target 23,2%
Spread / Lowest Target 3,09%
EPS Revisions
Managers and Directors
NameTitle
Graham David Mullis Chief Executive Officer & Executive Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
R. A. Trevor Chief Technology Officer
Lisa Henriet Director-Group Operations
Sector and Competitors
1st jan.Capitalization (M$)
NOVACYT-59.42%341
GILEAD SCIENCES, INC.16.98%85 472
MODERNA, INC.98.54%83 281
WUXI APPTEC CO., LTD.30.07%66 801
LONZA GROUP AG16.84%54 908
REGENERON PHARMACEUTICALS9.45%54 755